Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clinical investigation for the treatment of HCV infection. The poor fidelity of the HC...

Cijeli opis

Bibliografski detalji

Izdano u:	Antimicrob Agents Chemother
Glavni autori:	Lu, Liangjun, Pilot-Matias, Tami J., Stewart, Kent D., Randolph, John T., Pithawalla, Ron, He, Wenping, Huang, Peggy P., Klein, Larry L., Mo, Hongmei, Molla, Akhteruzzaman
Format:	Artigo
Jezik:	Inglês
Izdano:	American Society for Microbiology (ASM) 2004
Teme:	Antiviral Agents
Online pristup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC415624/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15155230/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.6.2260-2266.2004
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!